Title: Insulin Affordability Data Collection Act
Policy area: Health

Summary:
Insulin Affordability Data Collection Act
This bill requires the Department of Health and Human Services to conduct a study evaluating the impact of insulin affordability on the health outcomes of individuals who are reliant on insulin.

[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[H.R. 5691 Introduced in House (IH)]

<DOC>






116th CONGRESS
  2d Session
                                H. R. 5691

 To require the Secretary to conduct a study and issue a report on the 
                       affordability of insulin.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                            January 28, 2020

   Ms. Craig (for herself, Mr. Guest, Mr. Stauber, and Mr. Phillips) 
 introduced the following bill; which was referred to the Committee on 
                          Energy and Commerce

_______________________________________________________________________

                                 A BILL


 
 To require the Secretary to conduct a study and issue a report on the 
                       affordability of insulin.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Insulin Affordability Data 
Collection Act''.

SEC. 2. STUDY AND REPORT ON THE AFFORDABILITY OF INSULIN.

    The Secretary of Health and Human Services (referred to in this 
section as the ``Secretary''), acting through the Assistant Secretary 
for Planning and Evaluation, shall--
            (1) conduct a study that examines--
                    (A) for each type or classification of diabetes 
                (including type 1 diabetes, type 2 diabetes, 
                gestational diabetes, and other conditions causing 
                reliance on insulin), the effect of the affordability 
                of insulin on--
                            (i) adherence to insulin prescriptions;
                            (ii) rates of diabetic ketoacidosis;
                            (iii) downstream impacts of insulin 
                        adherence, including rates of dialysis 
                        treatment and end-stage renal disease;
                            (iv) spending by Federal health programs on 
                        acute episodes that could have been averted by 
                        adhering to an insulin prescription; and
                            (v) other factors, as appropriate, to 
                        understand the impacts of insulin affordability 
                        on health outcomes, Federal Government spending 
                        (including under the Medicare program under 
                        title XVIII of the Social Security Act (42 
                        U.S.C. 1395 et seq.) and the Medicaid program 
                        under title XIX of the Social Security Act (42 
                        U.S.C. 1396 et seq.)), and insured and 
                        uninsured individuals with diabetes; and
                    (B) among individuals who are unable to afford 
                insulin, the numbers of such individuals--
                            (i) who are uninsured;
                            (ii) who are covered under private health 
                        insurance; and
                            (iii) who are covered under public health 
                        insurance programs; and
            (2) not later than 2 years after the date of enactment of 
        this Act, submit to Congress a report on the study conducted 
        under paragraph (1).
                                 <all>